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Replacing GnRH agonist cotreatment for the prevention of a
premature rise in LH during ovarian stimulation for in vitro
fertilization (IVF) by the late follicular phase administration
of GnRH antagonist may render supplementation of the luteal
phase redundant, because of the known rapid recovery of
pituitary function after antagonist cessation.
This randomized two-center study was performed to com-
pare nonsupplemented luteal phase characteristics after
three different strategies for inducing final oocyte matura-
tion. Forty patients underwent ovarian stimulation using re-
combinant (r-)FSH (150 IU/d, fixed) combined with a GnRH
antagonist (antide; 1 mg/d) during the late follicular phase.
When at least one follicle above 18 mm was observed, patients
were randomized to induce oocyte maturation by a single
injection of either r-human (h)CG (250g) (n 11), r-LH (1 mg)
(n  13), or GnRH agonist (triptorelin; 0.2 mg) (n  15). Re-
trieved oocytes were fertilized by either IVF or intracytoplas-
matic sperm injection, depending on sperm quality. Embryo
transfer was performed 3–4 d after oocyte retrieval. No luteal
support was provided. Serum concentrations of FSH, LH, es-
tradiol (E2), progesterone (P), and hCG were assessed at fixed
intervals during the follicular and luteal phase.
The median duration of the luteal phase was 13, 10, and 9 d
for the r-hCG, the r-LH, and the GnRH agonist group, respec-
tively (P  0.005). The median area under the curve per day
(from 4 d post randomization until the onset of menses) for LH
was 0.50, 2.34, and 1.07 for the r-hCG, the r-LH, and the GnRH
agonist group, respectively (P  0.001). The median area un-
der the curve per day for P was 269 vs. 41 and 16 for the r-hCG,
the r-LH, and the GnRH agonist group, respectively (P <
0.001). Low pregnancy rates (overall, 7.5%; range, 0–18% per
started cycle) were observed in all groups.
In conclusion, the nonsupplemented luteal phase was in-
sufficient in all three groups. In the patients receiving r-hCG,
the luteal phase was less disturbed, compared with both other
groups, presumably because of prolonged clearance of hCG
from the circulation and the resulting extended support of the
corpus luteum. Despite high P and E2 concentrations during
the early luteal phase in all three groups, luteolysis started
prematurely, presumably because of excessive negative ste-
roid feedback resulting in suppressed pituitary LH release.
Hence, support of corpus luteum function remains mandatory
after ovarian stimulation for IVF with GnRH antagonist
cotreatment. (J Clin Endocrinol Metab 88: 4186–4192, 2003)
THE USE OF GnRH agonist cotreatment in ovarian stim-ulation protocols for in vitro fertilization (IVF) results
in a short luteal phase and clearly reduced pregnancy rates
(1), unless luteal phase support is provided (2). In a recent
study, the luteal phase in IVF protocols using GnRH agonist
without luteal support was characterized by very high pro-
gesterone (P) and estradiol (E2) concentrations during the
early luteal phase (3). Subsequently, premature luteolysis
occurred during the midluteal phase. The corpus luteum
seemed to be driven by the human (h)CG bolus injection used
to induce final oocyte maturation during the late follicular
phase, because the decrease in P concentrations was strongly
correlated with the decrease in serum hCG levels (3). En-
dogenous LH levels remained low throughout the luteal
phase.
The reason for abnormal luteal function after ovarian stim-
ulation for IVF remains open for speculation. Possible mech-
anisms involved include: 1) continued down-regulation, at-
Abbreviations: AUC, Area under the curve; E2, estradiol; h, human;
ICSI, intracytoplasmatic sperm injection; IVF, in vitro fertilization; M II,
metaphase II; P, progesterone; r-, recombinant; TVS, transvaginal
ultrasound.
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tributable to preceding follicular phase GnRH agonist
coadministration, may retard pituitary recovery (4, 5); 2) the
induction of multiple follicle development per se could either
directly or indirectly influence the duration of the luteal
phase (6, 7); 3) the removal of large quantities of granulosa
cells at oocyte retrieval may diminish the most important
source of P synthesis by the corpus luteum, thus disrupting
the luteal phase (8, 9); 4) supraphysiological levels of steroids
[related to the higher number of corpora lutea (10)] during
the early luteal phase could directly inhibit LH release
via negative feedback actions at the hypothalamic-pituitary
axis (11).
The recent availability of GnRH antagonists for the pre-
vention of a premature LH rise in IVF has enabled luteal
phase characteristics after ovarian stimulation to be studied
in the absence of a GnRH agonist. In contrast to GnRH
agonist-induced pituitary desensitization [which suppresses
gonadotropin release for at least 2–3 wk after cessation of the
GnRH agonist (3, 5, 12)], gonadotropin levels recover within
24 h after stopping the GnRH antagonist (13–15). It has there-
fore been widely speculated that luteal phase supplementa-
tion may no longer be required in cycles where GnRH an-
tagonist cotreatment is applied (16). Recent data in
intrauterine insemination seem to support this contention
(17). However, in IVF cycles in which ovarian stimulation
was combined with a GnRH antagonist, the duration of the
luteal phase was reduced and LH levels were extremely low
(18–20). The use of a GnRH antagonist also allows the re-
assessment of the midcycle hCG bolus on corpus luteum
function, because hCG can now be replaced by either en-
dogenous or exogenous LH to induce final oocyte matura-
tion. Several studies have demonstrated the feasibility of
inducing an endogenous LH surge by administering a bolus
dose of GnRH agonist, both in patients treated with ovarian
stimulation alone (21, 22) and in patients cotreated with a
GnRH antagonist (23). Moreover, the recent availability of
recombinant (r-)LH enables an exogenous LH surge to be
used to induce final oocyte maturation during stimulation
(24). The current study was designed to reexamine luteal
characteristics after ovarian hyperstimulation for IVF. The
nonsupplemented luteal phase characteristics in patients co-
treated with GnRH antagonists were studied in women ran-
domized to three different approaches for the induction of
final oocyte maturation: r-hCG, r-LH, or an endogenous LH
surge induced by a GnRH agonist bolus.
Patients and Methods
Patients
This prospective randomized two-center trial was approved by the
local ethics review committees of both participating centers, and a signed
written informed consent was obtained from all patients. Inclusion cri-
teria were: 1) regular indication for IVF or IVF/intracytoplasmatic sperm
injection (ICSI); 2) no more than 38 yr of age; 3) regular menstrual cycles
(cycle length between 24–35 d); 4) both ovaries present; 5) absence of
uterine abnormalities that could impair embryo implantation or preg-
nancy evolution; 6) body mass index, 18–29 kg/m2; 7) no history of poor
ovarian response (less than three oocytes in a previous IVF cycle); and
finally, 8) no history of moderate or severe ovarian stimulation
syndrome.
Study protocol
After a negative pregnancy test (Clearview, hCG II; Unipath Ltd.,
Bedford, UK), ovarian stimulation was initiated on cycle d 2 or d 3 using
a fixed daily dose of r-hFSH (Gonal-F, Serono; 150 IU sc). The GnRH
antagonist (Antide, Serono; 1 mg daily sc) was initiated on the day that
the largest follicle was at least 14 mm in diameter (25) and was continued
up to and including the randomization day.
When at least one follicle was at least 18 mm, randomization was
carried out, by sealed envelopes, to one of three approaches for trig-
gering final oocyte maturation. For both centers, a separate stratified
randomization list was generated by computer. The three arms of this
study were: 1) r-hCG (Ovidrel, Serono), 250 g sc (26, 27); 2) r-LH
(Luveris, Serono), 1 mg sc (24); or 3) GnRH agonist (Decapeptyl; Ferring,
Hoofddorp, The Netherlands), 0.2 mg sc. Oocyte retrieval was per-
formed 35 h later. Insemination took place either by routine IVF or by
ICSI. In case of fertilization, a maximum of two embryos were trans-
ferred after 2–5 d of culture, according to local procedures. No luteal
support was provided. In the absence of menstrual bleeding, a urine or
serum pregnancy test was performed 15–20 d post randomization.
The ovarian response was monitored with transvaginal ultrasound
(TVS). TVS was performed at fixed days in the follicular phase, i.e.
stimulation d 1, d 6, and on the day of randomization. The frequency of
additional TVS depended on the diameter of the largest follicle. When
the largest follicle was no more than 12 mm, the patient returned 2 d
later; whereas when the largest follicle was more than 12 mm, she
returned the next day. This approach enabled the initiation of the GnRH
antagonist when the largest follicle was at least 14 mm.
Blood sampling was performed on stimulation d 1, on the day the
GnRH antagonist was initiated, on the day of randomization, just before
the administration of the randomized medication, on the day of the
oocyte retrieval, and every other day thereafter.
Hormone assays
Blood samples were centrifuged, and serum was frozen and stored
at 20 C. Serum was assayed for FSH, LH, E2, P, and hCG in the same
laboratory. From each patient, hormone assays were performed in the
same run. All measurements were performed by immunofluorometric
assay (Immulite 2000; Diagnostic Products Corp., Los Angeles, CA).
Intra- and interassay variations were, respectively, less than 5% and less
than 8% for FSH; less than 3% and less than 6% for LH; less than 6 and
less than 16% for P; less than 8% and less than 11% for E2, and less than
6% and less than 7% for hCG.
Study design and statistical analysis
In a previous study of IVF patients treated with ovarian stimulation
combined with a GnRH agonist, hCG (10,000 IU) for induction of final
oocyte maturation, and no luteal support, we observed a mean maxi-
mum P level in the luteal phase of 230 95 (sd) nm (3). We hypothesized
that in the absence of hCG, a difference in maximum P levels of 80 nm
could be expected. To test the hypothesis that substitution of hCG by an
exogenous or endogenous LH surge leads to a reduction in maximum
P levels of 80 nm with 90% power at a P value of 0.05 (two-sided,
assuming the overall sd  95 nm), 30 patients were needed for each
group, i.e. a total of 90 patients.
When 40 patients had been included, the study was canceled pre-
maturely because of observed premature luteal phase bleeding and
extremely low pregnancy rates. Preliminary observations highlighted a
wide variation in the luteal phase length, both within and between the
study groups (Fig. 1). Moreover, the differences in median maximum P
levels between groups were much larger than expected (Fig. 1). There-
fore, it was decided to analyze the data by comparing the area under the
curve (AUC) per day, in addition to maximum P levels. The AUC/d was
calculated from d 4 after randomization (to exclude the influence of the
LH surge) until onset of menses. The sum of the daily levels measured
was divided by the number of days until menses occurred. This results
in estimated mean concentrations of the various parameters per day.
This method of calculation results automatically in linear interpolation
of missing values, unless missing values occur at endpoints of the
interval. However, this did not occur: five patients had one missing
assay day, and one patient had 3 missing days, all in interior points of
the luteal interval.
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Endocrine profiles of all patients, including the pregnant patients per
randomized group, are depicted in Fig. 2. Because blood sampling was
carried out until 16 d post randomization, some endocrine data relate to
the follicular phase of the next cycle. To address this and to study the
endocrine characteristics associated with the length of the luteal phase,
we elected to reallocate the nonpregnant patients (n  34) to three
groups according to luteal phase duration. Before further analysis, the
patients were arbitrarily divided into groups based on luteal phase
lengths of no more than 9 d, 10–12 d, and at least 13 d, resulting in 10,
14, and 10, patients, respectively.
The Kruskal Wallis test was used to test the different parameters for
significance between the three groups. For the number of patients
achieving embryo transfer, pregnancy, and ongoing pregnancy, 2-by-3
cross-tables were produced and analyzed by Fisher’s exact test. Post hoc
comparisons between two groups were not performed because no spe-
cific hypotheses existed before starting the study. ANOVA on log-
transformed data was used to test whether differences among the three
randomized groups were dissimilar in the two centers. Associations
between continuous parameters were calculated by means of Spear-
man’s rank correlation. P values  0.05 were considered to indicate
significant differences.
Results
Before recruitment to the study was completed, it became
apparent that the length of the luteal phase was greatly
diminished in all three study groups (Fig. 1) and that preg-
nancy rates were unacceptably low (Table 1). The decision
was therefore made to cancel this study after 40 patients were
included. At this point, only two pregnancies in the r-hCG
and one pregnancy in the GnRH agonist group had been
obtained. This pregnancy rate of 7.5% per started cycle was
significantly lower than the 22% previously reported by our
group (28). One patient, randomized to the r-hCG group, was
excluded from further analyses because of premature
ovulation.
The overall median age of patients participating in this
study was 33.6 (range, 27.4–38.5) yr, median cycle length was
28 (range, 24–32 d) d, and median duration of infertility was
26 (range, 4–105) months. Median early follicular phase FSH
levels were 6.5 (range, 2.6–16.3) IU/liter. Median late follic-
ular phase levels (day of randomization) were: E2, 4,558
(range, 1,137–34,137) pm; LH, 1.7 (range, 0.5–10.8) IU/liter;
and P, 3.3 (range, 1.5–14.6) nm. These prerandomization pa-
rameters did not differ among groups (data not shown).
Follicular phase and luteal phase characteristics of the
treatment cycle, comparing the three different oocyte mat-
uration strategies, are shown in Table 1 and Fig. 1. Correcting
for center did not change any of these findings. The group by
center interaction in ANOVA (which tests for a center effect)
was never significant except for P AUC (P  0.04). Preran-
domization parameters, including duration of the follicular
phase, days of GnRH antagonist administration, and number
of follicles of at least 11 mm were not different among groups
(Table 1). Clinical outcome parameters, including number of
oocytes retrieved, number of embryo transfers, and preg-
nancy rates, were not significantly different among groups
(Table 1). The percentage of mature metaphase II (M II)
oocytes could only be assessed in the patients undergoing
ICSI. In the r-hCG group, eight patients underwent ICSI, and
85% of the oocytes were M II. For the r-LH group, five
patients underwent ICSI, and 80% of the oocytes were M II.
Finally, in the GnRH agonist group, eight patients under-
went ICSI, and 83% of the oocytes were M II (P 0.9). Hence,
FIG. 1. Box (median values and 25th and 75th percentiles) and whis-
ker (P5 and P95) plots representing the differences in the nonsupple-
mented luteal phase after induction of final oocyte maturation with
either r-hCG, r-LH, or GnRH agonist in the duration of the luteal
phase (calculated as interval between day of r-hCG, r-LH, or GnRH
agonist and onset of menstruation in nonpregnant patients), and
AUC/d of LH, FSH, E2, and P. To determine differences in luteal
hormone profiles, the AUC estimated from d 4 after randomization (to
exclude the influence of the LH surge) was divided by the number of
days, because the duration of the luteal phase showed a large vari-
ation. This value indicates a mean level of LH, E2, and P on each day
of the luteal phase (in nonpregnant patients). Differences in maxi-
mum P (P max) levels among the three groups are shown.
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it seems that all three methods resulted in adequate final
oocyte maturation.
Endocrine profiles of all patients (including the pregnant
patients) per randomized group are depicted in Fig. 2. Luteal
phase patterns of both gonadotropin and steroid levels were
significantly different among groups, as reflected by large
differences in the AUC/d for FSH, LH, E2, and P (Fig. 1).
The luteal phase hCG levels are depicted in Fig. 3. In
patients who received r-hCG to trigger final oocyte matu-
ration, hCG levels remained detectable until 10 d post ran-
domization, as shown before (3). In pregnant patients, hCG
levels began to increase 12 d post randomization, corre-
sponding, on average, with 4 d after implantation. The two
pregnant patients treated with r-hCG showed a decline of
hCG to 6 and 3 IU/liter on d 10 post randomization. In five
patients, a pregnancy was confirmed by a positive pregnancy
test between 15–20 d post randomization. Three patients
presented with an ongoing pregnancy (i.e. two singleton
pregnancies and one twin pregnancy). One patient suffered
from an ectopic pregnancy and one from an early miscar-
riage. In five other patients, hCG levels showed a slight rise,
up to 6 IU/liter at d 12 to 14 post randomization, despite
menses. In these patients, embryo implantation may have
occurred without progressing to a clinical pregnancy.
Possible correlations between late follicular phase E2 con-
centrations or luteal phase AUC LH, along with correlations
between AUC LH and AUC P and duration of the luteal
phase for women randomized for either r-LH or GnRH ag-
onist, are shown in Fig. 4.
Discussion
This study demonstrates, for the first time, that the non-
supplemented luteal phase is abnormal after ovarian stim-
ulation and GnRH antagonist cotreatment for IVF. This find-
ing was associated with such a low pregnancy rate that it was
deemed unethical to complete the study as originally de-
signed. Given that all patients have been cotreated with
GnRH antagonists, the degree of abnormality of the luteal
phase was striking.
Ovarian stimulation protocols for IVF normally include
the coadministration of GnRH agonists to prevent premature
luteinization. The resulting down-regulation of the pituitary
also leads to highly suppressed luteal phase LH levels, be-
cause pituitary recovery after cessation of GnRH agonist
takes 2–3 wk (3, 5, 12). In contrast, the recovery of pituitary
LH release is almost immediate after the cessation of GnRH
antagonist administration (13–16). This was reported for
FIG. 2. Box (median values and 25th
and 75th percentiles) and whisker (P5
and P95) plots representing FSH, LH,
E2, and P serum concentrations in all 39
subjects (with or without pregnancy) in
the nonsupplemented luteal phase after
induction of final oocyte maturation
with either r-hCG, r-LH, or GnRH ag-
onist. On the x-axis, the days of blood
sampling are given. r, Day of random-
ization;4, 4 d after randomization, i.e.
day of oocyte pick up; 8, 8 d after ran-
domization; and likewise for 12 and
16.
TABLE 1. Follicular and luteal phase characteristics (median and ranges) of 39 subjects undergoing ovarian stimulation for IVF using
r-hFSH/GnRH antagonist, randomized for three different strategies for the induction of final oocyte maturation
r-hCG (n  11) r-LH (n  13) GnRH agonist (n  15) P valuea
Duration follicular phase (d) 11 (9–14) 12 (10–14) 12 (9–16) 0.9
No. days GnRH antagonist 4 (3–8) 4 (3–6) 4 (2–7) 1.0
No. follicles  11 mm 7 (5–16) 8 (2–18) 9 (3–13) 0.8
No. oocytes retrieved 7 (3–23) 7 (1–26) 10 (1–17) 0.9
No. patients achieving embryo transferb 9 11 14 0.4
Pregnancyb 2 (18%) 1 (8%) 2 (13%) 0.8
Ongoing pregnancyb 2 (18%) 0 (0%) 1 (7%) 0.3
LH(day of oocyte retrieval) (IU/liter) 1.3 (0.3–2.9) 50.6 (3.7–54.1) 5.5 (2.0–9.6) 0.001
Day of Pmaximum 6 (6–8) 4 (4–6) 4 (4–6) 0.001
Day of decrease of P 8 (6–8) 4 (4–8) 4 (4–8) 0.001
a Parameters were tested for significance using Kruskal Wallis test.
b Calculated per randomized group and tested for significance using a two-tailed Fisher’s exact test.
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both ganirelix and for cetrorelix available on the market. For
antide, a GnRH antagonist used in the current study, rapid
recovery after cessation was also shown after a week of daily
injections in males (14). As-yet-unpublished data also show
the clinical feasibility of the use of antide in IVF patients. A
dose-dependent LH suppression was observed, involving
daily administration of antide doses ranging from 0.25–2 mg
(Lambalk, personal communication). The results of the cur-
rent study demonstrate, for the first time, that a rapid re-
covery of LH release does not occur after ovarian stimulation
for IVF and GnRH antagonist cotreatment. Alternative ex-
planations for the abnormal luteal phase under these con-
ditions are therefore warranted.
In the normoovulatory cycle, the midcycle LH surge in-
duces final oocyte maturation, luteinization of granulosa and
theca cells, and rupture of the Graafian follicle (29, 30). LH
also acts as a luteotropic hormone, because it promotes the
growth and the maintenance of the corpus luteum (30–32).
Indeed, animal and human studies have confirmed that with-
drawal of LH (by either cessation of exogenous support in the
hypogonadotropic hypogonadism model or by administer-
ing a GnRH analog) induces the initiation of luteolysis (33,
34), although the corpus luteum can survive the lack of
support for a limited number of days (35). In stimulated
cycles, luteal endocrine characteristics are dramatically al-
tered (1, 3, 6, 11), leading to premature luteolysis in non-
supplemented patients. As in the natural cycle, the formation
and maintenance of corpora lutea in stimulated cycles are
also dependent on sufficient support by endogenous LH.
When a large bolus dose of hCG is used to induce final oocyte
maturation in the late follicular phase, it also acts as a lu-
teotropic agent, and the corpora lutea are supported for 7–10
d (3). After this period, clearance of the exogenous hCG from
the circulation is complete, and the maintenance of the non-
supported corpora lutea becomes dependent on endogenous
LH production. Should LH levels be suppressed in this
phase, early luteolysis will occur.
Previously, our group studied LH surge characteristics
using different late follicular phase interventions in IVF pa-
tients using luteal phase supplementation (23). In the current
study, the nonsupplemented luteal phase LH profile and
corpus luteum function were closely monitored. The LH
surge clearly differed between the study groups, with the
highest levels assessed on the day of oocyte retrieval occur-
ring in women receiving r-LH. In contrast, LH levels in those
women receiving GnRH agonist were low, in agreement with
a relatively short duration of the induced endogenous LH
surge, as shown previously (23). In both the r-LH group and
those receiving GnRH agonist, the duration of the LH surge
was relatively short, with median LH levels less than 5 IU/
liter and less than 2 IU/liter, respectively, being observed 4 d
post randomization (Fig. 2). Because LH was assessed every
FIG. 3. hCG levels related to the time after induction of final oocyte
maturation with either r-hCG, r-LH, or GnRH agonist. On the x-axis,
the days of blood sampling are given.
FIG. 4. Scatter plots representing the correlation between E2 levels
on the day of randomization (r) vs. the duration of the luteal phase
(upper panel); between the AUC/d of LH vs. the AUC/d of P [both
estimated from d 4 after randomization (to exclude the influence of the
LH surge) divided by number of days] (middle panel); and between
AUC/d of LH vs. the duration of the luteal phase (lower panel). All
three scatterplots represent data after induction of final oocyte mat-
uration with either r-LH or GnRH (not r-hCG).
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other day, the precise characteristics of the LH surges could
not be assessed. The differences in observed LH levels did
not seem to have any impact on the induction of final oocyte
maturation itself, because the percentage of MII oocytes
seemed to be normal in all three groups (36). However, in
those patients receiving r-LH or GnRH agonist, early luteal
phase LH levels on d 2 and 4 post randomization were
positively correlated to P production, expressed as AUC/d
(r  0.62, P  0.002 for d 2; and r  0.69, P  0.001 for d 4,
respectively). Therefore, the lower the LH levels in the early
luteal phase, the lower the P production throughout the
luteal phase. This finding is consistent with earlier primate
data that showed that LH surges with a duration less than
48 h are insufficient to support, or even induce, the corpus
luteum (37).
After the end of the LH surge, continued luteal LH support
is necessary to prevent early luteolysis and, subsequently,
shortening of the luteal phase. In contrast to the previously
described rapid recovery in pituitary function after cessation
of GnRH antagonist (15), luteal phase LH levels in all three
groups were found to be impaired. Midluteal LH levels rep-
resented by the AUC/d for LH (arbitrarily assessed from d
4 post randomization until menses) was also positively cor-
related with AUC/d for P and with duration of luteal phase
(Fig. 4). The longest median duration of the luteal phase was
observed in the r-hCG group (P  0.001), again suggesting
extended corpus luteum support by hCG (Fig. 1).
Both luteal E2 and P concentrations were significantly
higher in the r-hCG group, compared with both other
groups, which may explain low LH levels through negative
steroid feedback activity. The suppressive effect of E2 on
pituitary LH release in the luteal phase has been previously
demonstrated (6). The strong negative correlation in those
patients not receiving r-hCG between E2 levels on the day of
randomization (associated with follicle number) and the du-
ration of the luteal phase (Fig. 4) provides further indirect
evidence that steroid levels determine luteal phase charac-
teristics. Those patients with a luteal phase length less than
9 d presented with higher median E2 levels (6238 pm), com-
pared with patients with a longer luteal phase length (3847
and 2263 pm in the groups with a luteal phase length of 10–12
d and 13 d, respectively). These observations imply that
mechanisms other than follicular phase GnRH analog co-
treatment are involved in the occurrence of suppressed luteal
phase gonadotropins.
In conclusion, our data demonstrate that the luteal phase
is insufficient after ovarian stimulation for IVF in combina-
tion with daily GnRH antagonist. This is the case whether
r-hCG, r-LH, or GnRH agonist is used to trigger final oocyte
maturation. The present study suggests that the insufficient
luteal phase is principally related to supraphysiological ste-
roid levels in the late follicular and early luteal phase (which
are both related to the number of developing follicles and
subsequent corpora lutea). Luteal support should therefore
be provided after ovarian stimulation combined with GnRH
antagonist.
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